Float Short %

14.27

Margin Of Safety %

Put/Call OI Ratio

0.12

EPS Next Q Diff

-0.17

EPS Last/This Y

1.76

EPS This/Next Y

0.51

Price

8.28

Target Price

18.57

Analyst Recom

1.71

Performance Q

11.74

Relative Volume

1.35

Beta

0.82

Ticker: ENTA

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-08-15	ENTA	8.01	0.05	0.00	2623
2025-08-18	ENTA	8.19	0.03	0.00	2440
2025-08-19	ENTA	8.44	0.03	0.00	2456
2025-08-20	ENTA	8.78	0.03	0.00	2454
2025-08-21	ENTA	8.59	0.03	0.00	2457
2025-08-22	ENTA	8.82	0.03	0.00	2457
2025-08-25	ENTA	8.65	0.03	0.00	2457
2025-08-26	ENTA	8.66	0.03	0.00	2457
2025-08-27	ENTA	8.52	0.03	0.00	2457
2025-08-28	ENTA	8.68	0.03	0.00	2457
2025-08-29	ENTA	8.39	0.03	0.69	2465
2025-09-02	ENTA	9.01	0.05	100.00	2551
2025-09-03	ENTA	8.8	0.11	0.00	2701
2025-09-04	ENTA	8.88	0.11	0.00	2706
2025-09-05	ENTA	8.86	0.11	0.06	2719
2025-09-08	ENTA	8.96	0.10	0.00	2773
2025-09-09	ENTA	9.05	0.10	0.00	2776
2025-09-10	ENTA	8.3	0.11	0.84	2779
2025-09-11	ENTA	8.65	0.13	0.00	2939
2025-09-12	ENTA	8.28	0.12	0.00	3208
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-08-15	ENTA	8.01	17.3	-	-4.01
2025-08-18	ENTA	8.19	34.9	-	-4.01
2025-08-19	ENTA	8.39	34.9	-	-4.01
2025-08-20	ENTA	8.78	34.9	-	-4.01
2025-08-21	ENTA	8.55	34.9	-	-4.01
2025-08-22	ENTA	8.82	23.0	-	-4.01
2025-08-25	ENTA	8.65	23.0	-	-4.01
2025-08-26	ENTA	8.65	23.0	-	-4.01
2025-08-28	ENTA	8.69	23.0	-	-4.01
2025-08-29	ENTA	8.40	23.0	-	-4.01
2025-09-02	ENTA	9.02	23.0	-	-3.69
2025-09-03	ENTA	8.82	23.0	-	-3.69
2025-09-04	ENTA	8.90	23.0	-	-3.69
2025-09-05	ENTA	8.85	23.0	-	-3.72
2025-09-08	ENTA	8.91	25.4	-	-3.72
2025-09-09	ENTA	9.00	25.4	-	-3.72
2025-09-10	ENTA	8.31	25.4	-	-3.72
2025-09-11	ENTA	8.66	25.4	-	-3.72
2025-09-12	ENTA	8.28	25.4	-	-3.72
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-08-15	ENTA	0.00	-8.75	13.75
2025-08-18	ENTA	0.00	-11.41	13.75
2025-08-19	ENTA	0.00	-11.41	13.75
2025-08-20	ENTA	0.00	-11.41	13.75
2025-08-21	ENTA	0.00	-11.41	13.75
2025-08-22	ENTA	0.00	-11.41	13.75
2025-08-25	ENTA	0.00	-1.98	13.75
2025-08-26	ENTA	0.00	-1.98	13.75
2025-08-27	ENTA	0.00	-1.98	14.53
2025-08-28	ENTA	0.00	-1.98	14.53
2025-08-29	ENTA	0.00	-1.98	14.53
2025-09-02	ENTA	0.00	-1.90	14.53
2025-09-03	ENTA	0.00	-1.90	14.53
2025-09-04	ENTA	0.00	-1.90	14.53
2025-09-05	ENTA	0.00	-1.90	14.53
2025-09-08	ENTA	0.00	-2.01	14.53
2025-09-09	ENTA	0.00	-2.01	14.53
2025-09-10	ENTA	0.00	-2.01	14.53
2025-09-11	ENTA	0.00	-2.01	14.27
2025-09-12	ENTA	0.00	-2.01	14.27
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.85

Avg. EPS Est. Current Quarter

-1.01

Avg. EPS Est. Next Quarter

-1.02

Insider Transactions

Institutional Transactions

-2.01

Beta

0.82

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

91.9

Max Drawdown 5-Year %

-95.6

Target Price

18.57

P/E

Forward P/E

PEG

P/S

2.73

P/B

2.23

P/Free Cash Flow

EPS

-4.32

Average EPS Est. Cur. Y

-3.72

EPS Next Y. (Est.)

-3.21

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-141.98

Relative Volume

1.35

Return on Equity vs Sector %

-140.9

Return on Equity vs Industry %

-127.8

EPS 1 7Days Diff

EPS 1 30Days Diff

0.5

EBIT Estimation

Enanta Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 131

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

stock quote shares ENTA – Enanta Pharmaceuticals Inc Stock Price stock today

news today ENTA – Enanta Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch ENTA – Enanta Pharmaceuticals Inc yahoo finance google finance

stock history ENTA – Enanta Pharmaceuticals Inc invest stock market

stock prices ENTA premarket after hours

ticker ENTA fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: ENTA

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y